Mitoxantrone and ifosfamide as second-line therapy of epithelial ovarian cancer. A pilot study by the I.T.M.O. Group

Eur J Cancer. 1994;30A(14):2188. doi: 10.1016/0959-8049(94)00358-c.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Female
  • Humans
  • Ifosfamide / administration & dosage
  • Middle Aged
  • Mitoxantrone / administration & dosage
  • Ovarian Neoplasms / drug therapy*
  • Pilot Projects
  • Treatment Outcome

Substances

  • Mitoxantrone
  • Ifosfamide